BRMS1 and hepatocellular carcinoma: Consistently, DAPK1 has been identified as a appealing transcriptional target of BRMS1 and the luciferase units of -200 to -80 bp region of the DAPK1 promoter can be enhanced by BRMS1 in hepatocellular carcinoma cells [12].